The Indian Pharmacopoeia Commission has published the Indian Pharmacopoeia 2022 to supplement the current Indian Pharmacopoeia – the book of standards under the Drugs and Cosmetics Act,1940. IP 2022 is likely to be effective from December 1, 2022.
2022 Regulatory Activity in the Pharmaceutical Sector of India natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
: Monday, May 3, 2021, 7:52 PM IST
COVID-19: What is AYUSH 64? All you need to know about the Ayurvedic drug the govt is recommending to treat mild covid cases
The drug has been found very useful in treating mild to moderate cases of Covid-19 in clinical trials
Given the rise in the cases of COVID-19 in India, the Ayush Ministry has taken steps to increase the availability of Polyherbal drug AYUSH 64 across the country. As per the ministry, the drug has been found very useful in treating mild to moderate cases of Covid-19 in clinical trials.
What is Ayush 64?
The polyherbal Ayurvedic medicine mant for treating of COVID-19 has been one of the most significant developments. Originally developed in 1980 for treatment of malaria, it complies with all regulatory requirements and quality and pharmacopoeial standards. CCRAS recently concluded extensive robust clinical trials of the drug focusing on the management of asymptomatic, mild to moderate coronavirus in collaboration with the